Side Effects

GLP-1 and Gallbladder Problems: What Patients Need to Know

6 min read · Published 04-26-2026 · Sources cited to FDA / NIH / clinical trials

Yes, GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are associated with a higher risk of gallstones and gallbladder inflammation. The FDA has included gallbladder disease as a labeled warning for these medications. Understanding why this happens and which symptoms to watch for can help you catch problems early.

Why Do GLP-1 Medications Affect the Gallbladder?

Two overlapping mechanisms are believed to be responsible.

First, GLP-1 receptor agonists slow gastric emptying and reduce the hormonal signals that normally trigger the gallbladder to contract and release bile after meals. When the gallbladder does not empty regularly, bile becomes concentrated. Over time, cholesterol crystals can form and clump into gallstones — a process called cholelithiasis.

Second, rapid weight loss itself — regardless of how it is achieved — is a well-established risk factor for gallstones. When the body breaks down fat quickly, the liver secretes more cholesterol into bile, tipping the chemical balance toward stone formation. Because GLP-1 medications often produce significant and rapid weight loss, the two risk factors compound each other. The STEP 1 trial of semaglutide (Wilding et al., NEJM, 2021) reported that participants losing the most weight also had a higher incidence of gallbladder-related events compared with placebo.

How Common Is Gallbladder Disease on GLP-1 Therapy?

In clinical trials submitted for FDA approval, gallbladder-related adverse events occurred in roughly 1.6% to 2.6% of people taking semaglutide for weight management, compared with about 1% in the placebo groups. Events included gallstones, acute cholecystitis (gallbladder inflammation), choledocholithiasis (stones in the bile duct), and cholecystectomy (surgical removal of the gallbladder).

The absolute risk remains relatively low, but it is meaningfully higher than background rates. Patients with pre-existing obesity, a personal or family history of gallstones, or those losing weight very rapidly may face a greater-than-average risk.

What Are the Warning Signs of a Gallbladder Problem?

Gallstone symptoms can be easy to dismiss as general GI side effects of GLP-1 therapy. Knowing the distinction matters because untreated gallbladder disease can escalate to serious infection or bile duct obstruction.

  • Biliary colic: A sudden, intense pain in the upper right or upper middle abdomen, often starting 30–60 minutes after a fatty meal and lasting from a few minutes to several hours.
  • Pain radiating to the right shoulder or back: A hallmark of gallbladder origin, not typical GLP-1 nausea.
  • Nausea and vomiting that feel different from usual: More intense, tied to meals, or accompanied by the abdominal pain described above.
  • Fever or chills: May signal cholecystitis or cholangitis — both medical emergencies.
  • Yellowing of the skin or eyes (jaundice): Suggests a stone has moved into and is blocking the bile duct — seek emergency care immediately.
  • Dark urine or pale stools: Additional signs of bile duct obstruction.

Most important: Upper right abdominal pain combined with fever and nausea is not a routine GLP-1 side effect — it can indicate acute cholecystitis or a blocked bile duct. Go to an emergency room or call your prescriber immediately if you experience this combination of symptoms.

How Does Risk Progress Over Time on GLP-1 Therapy?

Gallbladder events are not uniformly distributed across a course of treatment. The period of fastest weight loss — typically the first several months — appears to carry the highest risk, because bile chemistry is most disrupted when fat is being metabolized rapidly. The table below outlines the general risk pattern.

Time on Medication Typical Weight Loss Phase Relative Gallbladder Risk What to Watch For
Weeks 1–4 Dose titration begins; early loss Low to moderate Distinguish nausea from meal-related pain
Weeks 5–16 Accelerating weight loss Moderate to higher Monitor for upper right abdominal pain after meals
Weeks 17–52 Continued loss toward plateau Moderate (still elevated) Any new GI symptoms warrant discussion with prescriber
Beyond 1 year Weight maintenance or slow loss Lower but not zero Annual check-in on GI health recommended

Can You Reduce Your Gallbladder Risk While on GLP-1 Therapy?

Complete prevention is not guaranteed, but several evidence-informed strategies may lower your personal risk:

  • Eat regular, moderate-fat meals. Skipping meals or following a very low-fat diet reduces the natural stimulus for the gallbladder to contract and empty, allowing bile to stagnate. A small amount of healthy fat at each meal encourages regular gallbladder emptying.
  • Avoid crash dieting alongside medication. Extremely low-calorie diets on top of GLP-1 therapy can accelerate weight loss to a rate that dramatically increases cholesterol secretion in bile. Aim for the steady, gradual loss your prescriber targets.
  • Stay hydrated. Adequate water intake supports bile fluidity.
  • Discuss ursodeoxycholic acid (UDCA) with your doctor if you are high risk. In people undergoing rapid weight loss through bariatric surgery, UDCA (a bile acid medication) has been shown to reduce gallstone formation. Whether the same benefit applies to GLP-1 users is under study, but some clinicians consider it for very high-risk patients.
  • Report new abdominal symptoms promptly. Early diagnosis of biliary colic allows for management before a more serious complication develops.

Frequently Asked Questions

Possibly, but this decision belongs to your prescriber and potentially a gastroenterologist. Existing asymptomatic gallstones may be monitored, but active gallbladder disease is generally considered a reason to proceed with caution or delay starting therapy. Always disclose your gallbladder history before starting a GLP-1 medication.
Gallbladder events appear across the GLP-1 drug class and are listed in FDA labeling for semaglutide and tirzepatide. Head-to-head comparisons between individual agents are limited. The risk is thought to be partly drug-driven and partly weight-loss-driven, so medications producing greater weight loss may carry somewhat higher gallbladder risk.
Typical GLP-1 nausea tends to be mild to moderate, not localized to one spot, and improves as your body adjusts to the dose. A gallbladder attack usually involves sharp or cramping pain specifically in the upper right abdomen, often triggered by a fatty meal, and may radiate to the shoulder or back. Fever is never a GLP-1 side effect and always warrants medical attention.
Not always. Asymptomatic gallstones discovered incidentally are often monitored rather than immediately treated. Symptomatic stones causing repeated biliary colic, or complications like cholecystitis, typically do require laparoscopic cholecystectomy. Your gastroenterologist or surgeon will determine the appropriate approach based on the severity and frequency of your symptoms.
Current FDA labeling does not require a baseline abdominal ultrasound before starting GLP-1 therapy. However, if you have a history of gallstone disease, prior biliary symptoms, or other risk factors, your prescriber may order one to establish a baseline. Ask your doctor whether this is appropriate for your specific situation.
This depends on the severity of the gallbladder event. For mild, isolated biliary colic, some prescribers continue the medication with monitoring. For acute cholecystitis or more serious complications, temporary or permanent discontinuation is often recommended. Never make this decision on your own — contact your prescriber as soon as symptoms develop.
Yes. Obesity is an independent risk factor for gallstone disease, as documented in gastroenterology literature including Frossard et al. (Gastroenterology, 2016). GLP-1 medications add an additional, medication-related layer of risk on top of the baseline elevated risk that already exists in many of the patients they are prescribed to. This makes monitoring especially important in this population.

Gallbladder complications are a real but manageable risk of GLP-1 therapy. Knowing the warning signs, eating in ways that support regular gallbladder emptying, and reporting any new abdominal symptoms promptly can make a significant difference in outcomes. Talk openly with your prescriber about your personal gallbladder risk before starting or continuing a GLP-1 medication — they can help you weigh the benefits against this and other risks, and decide whether additional monitoring is right for you.

Sources
  • FDA, 'Ozempic (semaglutide) Prescribing Information', U.S. Food and Drug Administration, 2023
  • FDA, 'Wegovy (semaglutide) Prescribing Information', U.S. Food and Drug Administration, 2023
  • Wilding JPH et al., 'Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)', New England Journal of Medicine, 2021
  • Frossard JL et al., 'Gallstone Disease and Obesity: Mechanisms, Risk, and Management', Gastroenterology, 2016
  • Nauck MA et al., 'GLP-1 Receptor Agonists and the Gallbladder: A Safety Review', Diabetes Care, 2021

Keep Reading

Headaches on Semaglutide: What Causes Them and When They StopResearch & News · 6 min readOzempic Burps: Why Sulfur Burps Happen and How to Stop ThemResearch & News · 7 min read

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.